|
US2008248114A1
|
|
Oral osmotic drug delivery system
|
|
WO2008115574A1
|
|
Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
|
|
WO2008115529A1
|
|
Compositions comprising omega-3 fatty acids and cetp inhibitors
|
|
WO2008112227A1
|
|
Treatment with nicorandil and omega-3 fatty acids, and a combination product thereof
|
|
WO2008094450A1
|
|
Treatment of osteoarthritis with omega-3 fatty acids
|
|
WO2008088808A1
|
|
Treatment with non-steroidal anti-inflammatory drugs and omega-3 fatty acids, and a combination product thereof
|
|
WO2008066745A1
|
|
Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
|
|
WO2008088415A1
|
|
Omega-3 fatty acids for reduction of lp-pla2 levels
|
|
MX2009003928A
|
|
Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof.
|
|
CN101553221A
|
|
Statin and omega-3 fatty acids for reduction of APO-B levels
|
|
EP2083815A2
|
|
Statin and omega-3 fatty acids for reduction of apo-b levels
|
|
US2008085911A1
|
|
Statin and omega-3 fatty acids for reduction of apo-b levels
|
|
WO2008011178A2
|
|
Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
|
|
EP2049098A2
|
|
Omega-3 fatty acids for use in treating resistant hypertension
|
|
EP2081550A2
|
|
Coating capsules with active pharmaceutical ingredients
|
|
WO2007098020A2
|
|
Methods of screening patients for omega-3 fatty acid therapy
|
|
EP1973536A2
|
|
Treatment of fatty liver
|
|
US2008152718A1
|
|
System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
|
|
CN101252837A
|
|
Treatment with dihydropyridine calcium channel blockers and Omega-3 fatty acids and a combination product thereof
|
|
AU2006270047A1
|
|
Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
|
